WallStreetZenWallStreetZen

NASDAQ: GERN
Geron Corp Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for GERN

Based on 3 analysts offering 12 month price targets for Geron Corp.
Min Forecast
$3.00+28.21%
Avg Forecast
$3.67+56.71%
Max Forecast
$4.00+70.94%

Should I buy or sell GERN stock?

Based on 3 analysts offering ratings for Geron Corp.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GERN stock forecasts and price targets.

GERN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Needham
Bottom 15%
15
BuyMaintains$3.00+28.21%2022-08-12
B. Riley Securities
Bottom 2%
2
Strong BuyReinstates$4.00+70.94%2022-07-28
Baird
Top 15%
86
BuyInitiates Coverage On$4.00+70.94%2021-11-02

1 of 1

Forecast return on equity

Is GERN forecast to generate an efficient return?
Company
-2.66%
Industry
18.02%
Market
121.74%
GERN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GERN forecast to generate an efficient return on assets?
Company
-1.59%
Industry
13.83%
GERN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GERN earnings per share forecast

What is GERN's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.36
Avg 2 year Forecast
-$0.36
Avg 3 year Forecast
-$0.22

GERN revenue forecast

What is GERN's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$430.0k-68.03%
Avg 2 year Forecast
$3.8M+182.53%
Avg 3 year Forecast
$88.4M+6,468.77%
GERN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GERN revenue growth forecast

How is GERN forecast to perform vs Biotechnology companies and vs the US market?
Company
272.67%
Industry
24.14%
Market
8.59%
GERN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GERN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GERN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GERN$2.34$3.67+56.71%Strong Buy
QURE$18.76$50.75+170.52%Strong Buy
KNSA$12.84$34.00+164.80%Strong Buy
TGTX$5.92$20.60+247.97%Hold
KURA$13.66$30.80+125.48%Strong Buy

Geron Stock Forecast FAQ

Is Geron Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: GERN) stock is to Strong Buy GERN stock.

Out of 3 analysts, 1 (33.33%) are recommending GERN as a Strong Buy, 2 (66.67%) are recommending GERN as a Buy, 0 (0%) are recommending GERN as a Hold, 0 (0%) are recommending GERN as a Sell, and 0 (0%) are recommending GERN as a Strong Sell.

If you're new to stock investing, here's how to buy Geron stock.

What is GERN's earnings growth forecast for 2022-2024?

(NASDAQ: GERN) Geron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Geron's earnings in 2022 is -$116,929,000.On average, 3 Wall Street analysts forecast GERN's earnings for 2022 to be -$136,014,795, with the lowest GERN earnings forecast at -$154,905,739, and the highest GERN earnings forecast at -$120,902,040. On average, 3 Wall Street analysts forecast GERN's earnings for 2023 to be -$136,014,795, with the lowest GERN earnings forecast at -$158,683,928, and the highest GERN earnings forecast at -$117,123,851.

In 2024, GERN is forecast to generate -$83,120,153 in earnings, with the lowest earnings forecast at -$102,011,096 and the highest earnings forecast at -$60,451,020.

What is GERN's revenue growth forecast for 2022-2024?

(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 272.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.14%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Geron's revenue in 2022 is $1,345,000.On average, 3 Wall Street analysts forecast GERN's revenue for 2022 to be $162,462,116, with the lowest GERN revenue forecast at $147,349,361, and the highest GERN revenue forecast at $188,909,438. On average, 3 Wall Street analysts forecast GERN's revenue for 2023 to be $1,435,711,725, with the lowest GERN revenue forecast at $151,127,550, and the highest GERN revenue forecast at $3,929,316,300.

In 2024, GERN is forecast to generate $33,380,297,606 in revenue, with the lowest revenue forecast at $19,042,071,300 and the highest revenue forecast at $47,718,523,913.

What is GERN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: GERN) forecast ROA is -1.59%, which is lower than the forecast US Biotechnology industry average of 13.83%.

What is GERN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year GERN price target, the average GERN price target is $3.67, with the highest GERN stock price forecast at $4.00 and the lowest GERN stock price forecast at $3.00.

On average, Wall Street analysts predict that Geron's share price could reach $3.67 by Aug 12, 2023. The average Geron stock price prediction forecasts a potential upside of 56.71% from the current GERN share price of $2.34.

What is GERN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: GERN) Geron's current Earnings Per Share (EPS) is -$0.33. On average, analysts forecast that GERN's EPS will be -$0.36 for 2022, with the lowest EPS forecast at -$0.41, and the highest EPS forecast at -$0.32. On average, analysts forecast that GERN's EPS will be -$0.36 for 2023, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at -$0.31. In 2024, GERN's EPS is forecast to hit -$0.22 (min: -$0.27, max: -$0.16).

What is GERN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: GERN) forecast ROE is -2.66%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.